GREENWICH LIFESCIENCES, INC. Cash and Restricted Cash
GREENWICH LIFESCIENCES, INC. (GLSI) had Cash and Restricted Cash of $8.88 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-11
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $8.88M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $10.51M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $6.18M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $3.81M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $8.88M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $10.51M 10-Q · filed 2026-06-04 |
| 2025-12-31 | $6.18M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $3.81M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $3.13M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $2.75M 10-Q · filed 2026-06-04 |
| 2024-12-31 | $4.09M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $5.82M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $7.22M 10-Q · filed 2025-08-14 |
| 2024-03-31 | $5.51M 10-Q · filed 2025-05-20 |
| 2023-12-31 | $6.99M 10-K · filed 2026-06-01 |
| 2023-09-30 | $9.14M 10-Q · filed 2024-11-14 |
| 2022-12-31 | $13.47M 10-K · filed 2025-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |